US 12,303,479 B2
Chloride intracellular channel 1 for regulation of food intake
Olivia Osborn, Cardiff, CA (US); and Rizaldy Zapata, La Jolla, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/608,837
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed May 6, 2020, PCT No. PCT/US2020/031570
§ 371(c)(1), (2) Date Nov. 4, 2021,
PCT Pub. No. WO2020/227344, PCT Pub. Date Nov. 12, 2020.
Claims priority of provisional application 62/843,862, filed on May 6, 2019.
Prior Publication US 2022/0313636 A1, Oct. 6, 2022
Int. Cl. A61K 31/192 (2006.01); A61K 31/155 (2006.01); A61K 31/365 (2006.01); A61K 31/47 (2006.01); A61K 31/57 (2006.01); A61K 31/704 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 31/155 (2013.01); A61K 31/365 (2013.01); A61K 31/47 (2013.01); A61K 31/57 (2013.01); A61K 31/704 (2013.01)] 10 Claims
 
1. A method of inhibiting appetite, hyperphagia, obesity, hunger or weight gain, reducing food intake, or inducing weight loss, in a subject comprising administering to a subject in need an effective amount of a chloride intracellular channel protein 1 (Clic1) inhibitor or antagonist, wherein the Clic1 inhibitor is not metformin.